MEI Pharma, Inc. (NASDAQ:MEIP)

CAPS Rating: 1 out of 5

A development stage company, engaged in the clinical development of the anti-cancer drug phenoxodiol.

Recs

1
Player Avatar zzlangerhans (99.78) Submitted: 9/30/2011 9:36:21 PM : Underperform Start Price: $9.20 MEIP Score: +10.55

Seeking Alpha puff pieces notwithstanding, the long term prospects for Marshall Edwards remain dim. The company continues to putter with the dregs of the plant flavonoid oncology pipeline inherited from Daddy Novogen, another dead stock walking. The million or two that the company can raise from dilutive financings every quarter aren't likely to be sufficient to complete any phase II trials. Keep in mind this is a 12M cap stock, and in the wacky world of nano-cap anything can happen in the short term.

Featured Broker Partners


Advertisement